A carregar...
Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab
The development of checkpoint inhibitors has changed the treatment paradigm for cancer. Checkpoint inhibitors nivolumab, pembrolizumab, and cemiplimab target programmed death-1 (PD-1), whereas durvalumab, avelumab, and atezolizumab target PD-ligand 1. Ipilimumab targets cytotoxic T lymphocyte–associ...
Na minha lista:
| Publicado no: | South Med J |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott Williams & Wilkins
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7587235/ https://ncbi.nlm.nih.gov/pubmed/33140115 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14423/SMJ.0000000000001166 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|